Research developed at Purdue University and licensed by a biomedical startup could give patients with late-stage prostate cancer an alternative to hormone therapies that can develop resistance after prolonged use.
Eli Lilly and Co. is pledging $90 million over five years to improve access to treatment for diabetes, cancer and tuberculosis in developing countries—the latest push in its philanthropic strategy of building health care systems around the world and increasing the market for its prescription drugs.
Rx Help Centers, which helps insured and uninsured patients extract discounts on brand-name and generic drugs, has grown rapidly since shifting its focus from individuals to employers last year.
The National Institute on Aging is awarding $25 million to the Alzheimer's Disease Precision Models Center, a joint project of the Indiana University School of Medicine in Indianapolis and The Jackson Laboratory in Bar Harbor.
Companies like Eli Lilly and Co. unit Elanco are focused on developing vaccines as alternatives to antibiotics.
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
The money will be awarded from IU’s Grand Challenges Program, a new push that is designed to tackle “major and large-scale problems facing humanity” that can only be addressed by multidisciplinary research teams.
Animated Dynamics Inc. has raised $1.7 million in early funding to help it get its technology to market.
The competition heated up in the $71.5 billion global diabetes market last year after Indianapolis-based Eli Lilly’s and Boehringer Ingelheim’s Jardiance unexpectedly reduced the risk of heart attacks, strokes and deaths in a study.
State health officials are urging Indiana's health care providers to aggressively test patients for syphilis.
The Indianapolis-based drugmaker said Tuesday it has built a robust pipeline of drugs that “has the potential” to launch 20 new products in the 10 years between 2014 and 2023.
The Indiana Blood Center said it has been forced to defer up to 30 percent of donors at some post-spring break blood drives because they had traveled to areas where the Zika virus is being transmitted.
Indianapolis-based chemical manufacturer Vertellus Specialties Inc. has expanded its production capacity by 80 percent to keep up with customer demand for DEET, a common active ingredient in mosquito and tick repellents.
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo prolonged survival in cases of recurrent head and neck cancer, a first for patients with the harshest form of the disease who often face a bleak prognosis.
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
The national not-for-profit organization, trying to fight back against high-end gyms and boutique studios, is now a national model for diabetes prevention.
Shares in Eli Lilly and Co. fell Tuesday on concerns surrounding the potential approval of a drug designed to treat dementia caused by Alzheimer's disease.
Indianapolis' major hospitals will begin restricting visitors on Friday following a spike in emergency-room visits for flu-like symptoms, local health officials said Wednesday.
The new version of the Indiana bill would classify pseudoephedrine in a way that most consumers would be able to buy it, but pharmacists could require a prescription from suspicious customers.
Preferred Population Health Management is trying to get hospital systems, health insurers and area agencies on aging to use a set of tools and techniques to help dementia patients and their families—tools that were developed by the medical staff at Eskenazi Health, the Indiana University School of Medicine and the Regenstrief Institute.
